Performance of FDG PET/CT in the clinical management of breast cancer

Radiology

Volumn 266, Issue 2, 2013, Pages 388-405

  Groheux, David ^a,b   Espié, Marc ^a   Giacchetti, Sylvie ^a   Hindié, Elif ^b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADJUVANT THERAPY; ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISTANT METASTASIS; FALSE POSITIVE RESULT; FINE NEEDLE ASPIRATION BIOPSY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMAGE QUALITY; INFLAMMATORY BREAST CANCER; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAMMOGRAPHY; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; WHOLE BODY PET;

BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; SENTINEL LYMPH NODE BIOPSY;

EID: 84873374697     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12110853     Document Type: Article

References (93)

1. Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med 2008;49(6):938-955.
2. Blodgett TM, Meltzer CC, Townsend D W. PET/CT: form and function. Radiology 2007;242(2):360-385.
3. Groheux D, Giacchetti S, Rubello D, et al. The evolving role of PET/CT in breast cancer. Nucl Med Commun 2010;31(4):271-273.
4. Bos R, Van der Hoeven JJM, Van der Wall E, et al. Biologic correlates of (18) fuorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20(2):379-387.
5. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 1993;72(10):2979-2985.
6. Beaulieu S, Kinahan P, Tseng J, et al. SUV varies with time after injection in (18) F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 2003;44(7):1044-1050.
7. Stahl AR, Heusner TA, Hartung V, et al. Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs. J Nucl Med 2011;52(1):18-23.
8. Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F] fuorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009;96(2):166-170.
9. Buck A, Schirrmeister H, Kühn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29(10):1317-1323.
10. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42(1):9-16.
11. Crippa F, Seregni E, Agresti R, et al. Association between [18F]fuorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25(10):1429-1434.
12. Avril N, Rosé CA, Schelling M, et al. Breast imaging with positron emission tomography and fuorine-18 fuorodeoxyglucose: use and limitations. J Clin Oncol 2000;18(20):3495-3502.
13. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98(3):267-274.
14. Ikenaga N, Otomo N, Toyofuku A, et al. Standardized uptake values for breast carcinomas assessed by fuorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007;73(11):1151-1157.
15. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer 2007;14(3):260-268.
16. Ueda S, Tsuda H, Asakawa H, et al. Utility of 18F-fuoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 2008;8:165.
17. Buck AK, Schirrmeister H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004;31(Suppl 1):S80-S87.
18. Mavi A, Cermik TF, Urhan M, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med 2007;48(8):1266-1272.
19. Osborne JR, Port E, Gonen M, et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med 2010;51(4):543-550.
20. Nakajo M, Kajiya Y, Kaneko T, et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging 2010;37(11):2011-2020.
21. Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fuorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 2008;38(4):250-258.
22. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fuorine-18 fuorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008;112(5):995-1000.
23. Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011;38(3):426-435.
24. Groheux D, Moretti JL, Giacchetti S, et al. PET/CT in breast cancer: an update [in French]. Bull Cancer 2009;96(11):1053-1070.
25. Alberini JL, Lerebours F, Wartski M, et al. 18F-fuorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 2009;115(21):5038- 5047.
26. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dualtime-point imaging to improve breast cancer diagnosis with (18) F-FDG PET. J Nucl Med 2005;46(11):1819-1824.
27. Heusner TA, Kuemmel S, Umutlu L, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008;49(8):1215-1222.
28. Litmanovich D, Gourevich K, Israel O, Gallimidi Z. Unexpected foci of 18F-FDG uptake in the breast detected by PET/CT: incidence and clinical significance. Eur J Nucl Med Mol Imaging 2009;36(10):1558-1564.
29. Berg WA, Madsen KS, Schilling K, et al. Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology 2011;258(1):59-72.
30. Hindié E, Groheux D, Brenot-Rossi I, Rubello D, Moretti JL, Espié M. The sentinel node procedure in breast cancer: nuclear medicine as the starting point. J Nucl Med 2011;52(3):405-414.
31. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG; PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the Staging Breast Cancer with PET Study Group. J Clin Oncol 2004;22(2):277-285.
32. Veronesi U, De Cicco C, Galimberti VE, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18(3):473-478.
33. Cooper KL, Harnan S, Meng Y, et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2011;37(3):187-198.
34. Cooper KL, Meng Y, Harnan S, et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technol Assess 2011;15(4):iii-iv, 1-134.
35. Heusner TA, Kuemmel S, Hahn S, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 2009;36(10):1543-1550.
36. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010.
37. Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009;50(2):231-238.
38. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography fndings. Breast Cancer Res Treat 2008;109(3):417-426.
39. Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fuorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26(29):4746-4751.
40. Groheux D, Moretti JL, Baillet G, et al. Effect of (18) F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008;71(3):695-704.
41. Aukema TS, Straver ME, Peeters MJ, et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer 2010;46(18):3205-3210.
42. Segaert I, Mottaghy F, Ceyssens S, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J 2010;16(6):617-624.
43. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32(11):1253-1258.
44. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am 2007;45(4):669-676.
45. Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: sequential [18F]fuorodeoxyglucose positronemission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007;25(23):3440-3447.
46. Morris PG, Lynch C, Feeney JN, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010;28(19):3154-3159.
47. Heusner TA, Kuemmel S, Koeninger A, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010;37(6):1077-1086.
48. Groheux D, Giacchetti S, Espié M, et al. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med 2011;52(10):1526-1534.
49. NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 2. NCCN Web site. Published 2011. Updated January 5, 2011. Accessed January 31, 2011.
50. Fueger BJ, Weber WA, Quon A, et al. Performance of 2-deoxy-2-[F-18]fuoro- D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005;7(5):369-376.
51. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107(11):2545- 2551.
52. Haug AR, Schmidt GP, Klingenstein A, et al. F-18-fuoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr 2007;31(4):629-634.
53. Veit-Haibach P, Antoch G, Beyer T, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007;80(955):508-515.
54. Schmidt GP, Baur-Melnyk A, Haug A, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 2008;65(1):47-58.
55. Dirisamer A, Halpern BS, Flöry D, et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2010;73(2):294-299.
56. Aukema TS, Rutgers EJT, Vogel WV, et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 2010;36(4):387-392.
57. Grassetto G, Fornasiero A, Otello D, et al. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. Eur J Radiol 2011;80(3):828-833.
58. Evangelista L, Baretta Z, Vinante L, et al. Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging 2011;38(2):293-301.
59. Champion L, Brain E, Giraudet AL, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer 2011;117(8):1621-1629.
60. Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol 2010;136(7):1007-1022.
61. Pennant M, Takwoingi Y, Pennant L, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 2010;14(50):1-103.
62. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16(8):2672-2685.
63. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26(5):778-785.
64. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24(13):2019-2027.
65. Groheux D, Giacchetti S, Espié M, Rubello D, Moretti JL, Hindié E. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging 2011;38(3):419-425.
66. Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [(18) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18(8):1689-1695.
67. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18) F]-fuorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18(8):1676-1688.
68. Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fuorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24(34):5366-5372.
69. Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34(12):1915-1924.
70. McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007;102(1):75-84.
71. Duch J, Fuster D, Muñoz M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36(10):1551-1557.
72. Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009;19(6):1347-1357.
73. Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fuorodeoxyglucose. J Clin Oncol 2009;27(4):535-541.
74. Martoni AA, Zamagni C, Quercia S, et al. Early (18) F-2-fuoro-2-deoxy-d- glucose positron emission tomography may identify a subset of patients with estrogen receptorpositive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer 2010;116(4):805-813.
75. Groheux D, Hindié E, Giacchetti S, et al. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifes patients who are unlikely to achieve a pathologic complete response and are at high risk of early relapse. J Nucl Med 2012;53(2):249-254.
76. Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011;29(6):660-666.
77. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
78. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
79. Couturier O, Jerusalem G, N'Guyen JM, Hustinx R. Sequential positron emission tomography using [18F]fuorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006;12(21):6437-6443.
80. Specht JM, Tam SL, Kurland BF, et al. Serial 2-[18F] fuoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007;105(1):87-94.
81. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46(7):1144-1150.
82. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008;247(1):189-196.
83. Huyge V, Garcia C, Alexiou J, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol) 2010;22(10):818-827.
84. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fuorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35(13):1773-1782.
85. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-150S.
86. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 2005;23(8):1664-1673.
87. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic fare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26(1):51-56.
88. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptorpositive breast cancer. Breast Cancer Res Treat 2009;113(3):509-517.
89. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic fare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19(11):2797-2803.
90. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [(18) F]2-Deoxy-2-fuoro-D- glucose-positron emission tomography. J Cancer Res Clin Oncol 2004;130(5):273-278.
91. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fuoro[18F]- D-glucose. Cancer 1998;82(11):2227-2234.
92. Uematsu T, Kasami M, Yuen S. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy. Breast Cancer 2009;16(2):97-104.
93. Cachin F, Prince HM, Hogg A, Ware RE, Hicks RJ. Powerful prognostic stratification by [18F]fuorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006;24(19):3026-3031.